Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146144 | 1.00 | KIT (0.36) | KITPADI4PDPK1PIK3CDPIK3CG | |
| SCHEMBL31146259 | 0.84 | S1PR3 (0.33) | KITPDPK1BDKRB1S1PR3 | |
| SCHEMBL31146191 | 0.84 | S1PR3 (0.33) | KITPDPK1BDKRB1S1PR3 | |
| SCHEMBL31145872 | 0.84 | S1PR3 (0.33) | KITPDPK1BDKRB1S1PR3 | |
| SCHEMBL31146116 | 0.84 | S1PR3 (0.33) | KITPDPK1BDKRB1S1PR3 | |
| SCHEMBL31145833 | 0.81 | S1PR3 (0.35) | KITPDPK1PIK3CDPIK3CGBDKRB1 | |
| SCHEMBL31146187 | 0.81 | S1PR3 (0.35) | KITPDPK1PIK3CDPIK3CGBDKRB1 | |
| SCHEMBL31146003 | 0.80 | KIT (0.35) | KITPADI4PDPK1PIK3CDPIK3CG | |
| SCHEMBL31146043 | 0.80 | KIT (0.35) | KITPADI4PDPK1PIK3CDPIK3CG | |
| SCHEMBL31146062 | 0.79 | PADI4 (0.33) | PADI4PIK3CDPIK3CGMAPK1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206339-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | KIT 4199/4885PADI4 709/4885PDPK1 1251/4885 |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, COQ8A | KIT 4199/4885PADI4 709/4885PDPK1 1251/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | KIT 4407/4885PADI4 3264/4885PDPK1 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.